BUSINESSQUARTZ
Heart drug developer Kardigan is targeting a $1.4 billion valuation in its U.S. IPO
Kardigan, a heart drug developer, is targeting a $1.4 billion valuation through its U.S. IPO. The company plans to raise up to $373.3 million by selling 23.3 million shares priced between $14 and $16 each.
Related Signal
Adjacent reporting
- Antidepressant Drugmaker Seaport Seeks $212.4 Million in US IPO
- Cancer drug startup Parabilis Medicines is raising a record $670 million in its IPO
- Medical Device Maker Mobia Seeks to Raise $160 Million in US IPO
- SpaceX plans to raise $75B in its IPO
- Revolut targets a $200 billion IPO just months after its $75 billion share sale
- Canton Network developer Digital Asset eyes $300 million raise at $2 billion valuation, led by a16z crypto: Bloomberg